32.88
+0.41(+1.26%)
Currency In USD
Address
Generaal De Wittelaan L11 A3
Mechelen, 2800
Belgium
Phone
32 1 534 29 00
Website
Sector
Healthcare
Industry
Biotechnology
Employees
704
First IPO Date
February 27, 2012
| Name | Title | Pay | Year Born |
| Mr. Henry Gosebruch | Chief Executive Officer & Executive Director | 0 | N/A |
| Mr. Thad Huston C.M.A. | Executive Vice President, Chief Financial Officer & Chief Operating Officer | 0 | 1971 |
| Mr. Patrik Ringblom | Head of Strategy & US Lead | 0 | N/A |
| Ms. Ellen Van Der Aar | Head of Development | 0 | N/A |
| Dr. Pierre J.M.B. Raboisson Ph.D., Pharm.D. | Head of Small Molecules Discovery & Senior Vice President | 0 | N/A |
| Mr. Philippe Alen M.B.A., Ph.D., Pharm.D. | Senior Vice President & Head of Business Development | 0 | N/A |
| Ms. Alice Dietrich | Head of Medical Affairs | 0 | N/A |
| Marieke Vermeersch | Head of Corporate Communication | 0 | N/A |
| Ms. Valeria Cnossen | Executive Vice President & General Counsel | 0 | 1974 |
| Ms. Annelies Missotten | Executive Vice President & Chief Human Resources Officer | 0 | 1973 |
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.